Loading
A phase 3 trial testing SHR-A1921 in ovarian cancer, now recruiting.
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer is a phase 3 interventional study registered as NCT06394492, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Randomised, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer. Planned enrolment is 440 participants (estimated). The study started in 2024-05-10 and primary completion is expected in 2026-05-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A1921, Jiangsu Hengrui Pharmaceuticals.
Shares Platinum-resistant ovarian cancer, Jiangsu Hengrui Pharmaceuticals, Ovarian cancer.
Shares SHR-A1921, Jiangsu Hengrui Pharmaceuticals.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/